Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.44 |
| ▸ | FPR1 | P21462 | 4/20 | 0.44 |
| ▸ | FPR2 | P25090 | 4/20 | 0.44 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31098846 | 0.82 | FKBP4 (0.51) | MEN1KMT2ASSTR3FPR1FPR2 | |
| SCHEMBL5674052 | 0.80 | LMNA (0.56) | MEN1KMT2AMAPT | |
| SCHEMBL1087418 | 0.78 | MEN1 (0.43) | MEN1KMT2ASSTR3FPR1FPR2 | |
| SCHEMBL2387136 | 0.78 | SSTR3 (0.57) | MEN1KMT2ASSTR3FPR1FPR2 | |
| SCHEMBL27355181 | 0.78 | SSTR3 (0.57) | MEN1KMT2ASSTR3FPR1FPR2 | |
| SCHEMBL10440798 | 0.78 | SSTR3 (0.56) | MEN1KMT2ASSTR3MAPTSMN1; SMN2 | |
| SCHEMBL9680449 | 0.77 | FKBP4 (0.55) | MEN1KMT2ASSTR3FPR1FPR2 | |
| SCHEMBL8909746 | 0.76 | MEN1 (0.54) | MEN1KMT2ASSTR3FPR1FPR2 | |
| SCHEMBL28183355 | 0.76 | MEN1 (0.56) | MEN1KMT2ASSTR3FKBP4SMN1; SMN2 | |
| SCHEMBL3218655 | 0.75 | KMT2A (0.68) | MEN1KMT2AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101457218-A | Polylactic acid degrading enzyme with protein degrading activity | UNIV SHANDONG (CN) | 2009-06-17 | — | — | CN | claimed |
| US-9644194-B2 | Cold-adapted protease derived from Pseudoalteromonas arctica PAMC 21717 and uses thereof | KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY (KR) | 2017-05-09 | — | — | US | disclosed |
| US-9574185-B2 | Cold-adapted protease derived from Pseudoalteromonas arctica PAMC 21717 and uses thereof | KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY (KR) | 2017-02-21 | — | — | US | disclosed |
| US-8153413-B2 | High alkaline protease and use thereof | JAPAN AGENCY FOR MARINE-EARTH SCIENCE AND TECHNOLOGY (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20110124569-A1 | MACROCYCLIC COMPOUNDS, PROTEASE INHIBITION, AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110045570-A1 | NOVEL HIGH ALKALINE PROTEASE AND USE THEREOF | JAPAN AGENCY FOR MARINE-EARTH SCIENCE AND TECH. (JP) | 2011-02-24 | — | — | US | disclosed |
| CN-101457218-A | Polylactic acid degrading enzyme with protein degrading activity | UNIV SHANDONG (CN) | 2009-06-17 | — | — | CN | disclosed |
| WO-2009032349-A1 | MACROCYCLIC COMPOUNDS, PROTEASE INHIBITION, AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124569-A1 | MACROCYCLIC COMPOUNDS, PROTEASE INHIBITION, AND METHODS OF TREATMENT | PREP, SERPINB1, CTSC | MEN1 3548/4885KMT2A 2276/4885SSTR3 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.